Title | Rad regulation of CaV1.2 channels controls cardiac fight-or-flight response. |
Publication Type | Journal Article |
Year of Publication | 2022 |
Authors | Papa, A, Zakharov, SI, Katchman, AN, Kushner, JS, Chen, B-X, Yang, L, Liu, G, Jimenez, ASanchez, Eisert, RJ, Bradshaw, GA, Dun, W, Ali, SR, Rodriques, A, Zhou, K, Topkara, V, Yang, M, Morrow, JP, Tsai, EJ, Karlin, A, Wan, E, Kalocsay, M, Pitt, GS, Colecraft, HM, Ben-Johny, M, Marx, SO |
Journal | Nat Cardiovasc Res |
Volume | 1 |
Issue | 11 |
Pagination | 1022-1038 |
Date Published | 2022 Nov |
ISSN | 2731-0590 |
Abstract | Fight-or-flight responses involve β-adrenergic-induced increases in heart rate and contractile force. In the present study, we uncover the primary mechanism underlying the heart's innate contractile reserve. We show that four protein kinase A (PKA)-phosphorylated residues in Rad, a calcium channel inhibitor, are crucial for controlling basal calcium current and essential for β-adrenergic augmentation of calcium influx in cardiomyocytes. Even with intact PKA signaling to other proteins modulating calcium handling, preventing adrenergic activation of calcium channels in Rad-phosphosite-mutant mice (4SA-Rad) has profound physiological effects: reduced heart rate with increased pauses, reduced basal contractility, near-complete attenuation of β-adrenergic contractile response and diminished exercise capacity. Conversely, expression of mutant calcium-channel β-subunits that cannot bind 4SA-Rad is sufficient to enhance basal calcium influx and contractility to adrenergically augmented levels of wild-type mice, rescuing the failing heart phenotype of 4SA-Rad mice. Hence, disruption of interactions between Rad and calcium channels constitutes the foundation toward next-generation therapeutics specifically enhancing cardiac contractility. |
DOI | 10.1038/s44161-022-00157-y |
Alternate Journal | Nat Cardiovasc Res |
PubMed ID | 36424916 |
PubMed Central ID | PMC9681059 |
Grant List | R01 HL160089 / HL / NHLBI NIH HHS / United States S10 RR027050 / RR / NCRR NIH HHS / United States T32 HL120826 / HL / NHLBI NIH HHS / United States R01 HL151190 / HL / NHLBI NIH HHS / United States R01 HL113136 / HL / NHLBI NIH HHS / United States R01 HL155377 / HL / NHLBI NIH HHS / United States R01 HL136758 / HL / NHLBI NIH HHS / United States K08 HL153788 / HL / NHLBI NIH HHS / United States R01 NS110672 / NS / NINDS NIH HHS / United States R01 HL146149 / HL / NHLBI NIH HHS / United States P30 CA013696 / CA / NCI NIH HHS / United States F31 HL158232 / HL / NHLBI NIH HHS / United States R01 HL121253 / HL / NHLBI NIH HHS / United States K08 HL151969 / HL / NHLBI NIH HHS / United States K08 HL146964 / HL / NHLBI NIH HHS / United States R01 HL140934 / HL / NHLBI NIH HHS / United States R01 HL152236 / HL / NHLBI NIH HHS / United States R01 HL138528 / HL / NHLBI NIH HHS / United States |